AAN 2019

Complete Coverage

AAN: Isradipine Offers No Benefit in Parkinson Disease

HealthDay News — Isradipine does not appear to slow progression of disability in patients with de novo Parkinson disease (PD), according to a study presented at the annual meeting of the American Academy of Neurology, held from May 4 to 10 in Philadelphia. Tanya Simuni, MD, from the Northwestern University Feinberg School of Medicine in…
Next post in AAN 2019 Conference